Education, Science, Technology, Innovation and Life
Open Access
Sign In
  1. Home
  2. Journals
  3. MEDS Clinical Medicine
  4. Vol 3, Issue 4, 2022

Efficacy Analysis of Levofloxacin Combined with Cefoperazone/Sulbactam Sodium in the Treatment of Adult Bronchiectasis Complicated with Infection

Download as PDF

DOI: 10.23977/medsc.2022.030413 | Downloads: 18 | Views: 564

Author(s)

Yingjie Jiang 1,2, Jie Ren 1

Affiliation(s)

1 School of Pharmacy Changzhou University, Changzhou, 213000, China
2 Changzhou Jintan First People's Hospital, Changzhou, 213000, China

Corresponding Author

Jie Ren

ABSTRACT

Objective: To investigate the efficacy of levofloxacin combined with cefoperazone/ sulbactam sodium in the treatment of bronchiectasis complicated with infection in adults and its effect on lung function. Methods About 200 patients with bronchiectasis and infection from May 2019 to July 2022 in Jintan First People's Hospital of Changzhou City, Jiangsu Province were selected and divided into 2 groups (100 cases in each group) according to the treatment plan. The control group received cefoperazone /sulbactam sodium treatment, the observation group was treated with levofloxacin on the basis of the above. The evaluation was conducted by comparing the time of improvement of clinical symptoms, the decrease of inflammatory indicators, and the improvement of lung function indicators. Results After treatment, the overall effectiveness rate of the observation group was 93%, and the control group was 78%, which was significantly different (P<0.05), cough and sputum production, body temperature recovery and hemoptysis stop time were all earlier than those in the control group (P<0.05). Prior to treatment, there was no significant difference in neutrophil values (GRAN), white blood cell count (WBC), and hypersensitive C-reactive protein (CRP) between the two groups (P>0.05). After treatment, the GRAN, WBC and CRP of the control group were significantly higher than those in the observation group (P<0.05); there was no significant difference in forced expiratory volume (FVC), forced expiratory volume in 1 second (FEV1), FEV1/FVC between the two groups before treatment (P>0.05), After treatment, the FVC, FEV1, FEV1/FVC values in the observation group were significantly higher than those in the control group (P<0.05). Conclusion The application of levofloxacin combined with cefoperazone/sulbactam sodium can effectively improve the clinical symptoms, inflammation level and pulmonary function indexes of adult bronchiectasis complicated with infection.

KEYWORDS

levofloxacin, cefoperazone/sulbactam sodium, bronchiectasis, infection, pulmonary function

CITE THIS PAPER

Yingjie Jiang, Jie Ren, Efficacy Analysis of Levofloxacin Combined with Cefoperazone/Sulbactam Sodium in the Treatment of Adult Bronchiectasis Complicated with Infection. MEDS Clinical Medicine (2022) Vol. 3: 84-89. DOI: http://dx.doi.org/10.23977/medsc.2022.030413.

REFERENCES

[1] Yumin Zhou, Chen Wang,Wanzhen Yao, et al. Investigation on the disease and risk factors of bronchiectasis in residents aged 40 and above in 7 provinces and cities in China [J]. Chinese Journal of Internal Medicine,2013, 52(5): 379-382.  
[2] Li Yuling, Xing Fangyuan, Chen Jing, et al. Correlation between the incidence of years of onset in elderly patients with bronchiectasis and Pseudomonas aeruginosa infection and bronchial asthma [J]. Chinese Journal of Gerontology, 2015(3): 643-645. 
[3] Liu Youning,Chen Liang'an. Respiratory disease [J]. National Medical Journal of China,2002, 82(24): 1659-1660. 
[4] Liu Xuedong, Zhao Weiye, Zhang Shuli, et al. Research progress of bronchiectasis in adults [J]. Chinese Journal of Tuberculosis and Respiratory Diseases,2020, 43(10): 902-905. 
[5] Gao, Yonghua, Guan Weijie, Liu Shaoxia, et al. Aetiology of bronchiectasis in adults: A systematic literature review [J]. Respirology :2016, 21(8): 1376-1383.
[6] Hu Siyu, Long Fa, Long Liang, et al. Clinical efficacy and safety analysis of thermoplasty in the treatment of patients with severe asthma and asthma chronic obstructive pulmonary disease[J]. Chinese Journal of Internal Medicine,2021, 101(15): 1071-1076.
[7] Pan Jing, Lu Jinchang. Clinical features of COPD complicated with bronchiectasis and related factors [J]. Journal of Clinical Pulmonary Medicine, 2019, 24(9): 1645-1650. 
[8] JAMES D CHALMERS, PIETER GOEMINNE, STEFANO ALIBERTI, et al. The bronchiectasis severity index. An international derivation and validation study. [J]. American journal of respiratory and critical care medicine, 2014, 189(5): 576-585.
[9] Du Lijun, Dong Qiong. The distribution of pathogens in patients with bronchiectasis and lung infection and the effect of susceptibility test results on the application of antibacterial drugs [J]. Medical & Pharmaceutical Journal of Chinese People's Liberation Army,2022, 34(2): 66-69. 
[10] Qin Kejun, Cao Xianqin, Chen Paiqiang, et al. Clinical distribution and resistance mechanism of Pseudomonas aeruginosa [J]. Journal of Pathogen Biology, 2021, 16(2): 224-227.
[11] Guo Xiaofang. Analysis of resistance of Pseudomonas aeruginosa to β-lactam antibiotics [J]. Sichuan Journal of Physiological Sciences, 2019, 41(1): 15-17.
[12] Wang Yueping, Yin Feifei, Zhao Guohou, et al. Expression levels and significance of serum CRP, IL-6, and PCT in bronchiectasis complicated with pulmonary infection [J]. Chinese Journal of Nosocomiology, 2020, 30(9): 1350-1354. 
[13] Liu Hongmei, Wuyun Gaowa. Evaluation of lung function in patients with chronic obstructive pulmonary disease with bronchiectasis [J]. Chinese Journal of Community Physicians, 2020, 36(36): 112-113.

Subscription
E-Mail Alert
Most popular papers
Call for Special Issue
Publication Ethics & OA Statement
Plagiarism Policy
Contact Us
Downloads: 4275
Visits: 190052

Sponsors, Associates, and Links

All published work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright © 2016 - 2031 Clausius Scientific Press Inc. All Rights Reserved.